The price of a vital medicine for patients with primary immunodeficiency has increased from 120,000 tomans to 6 million and 300,000 tomans; a jump that has made covering treatment costs difficult for many families.

At the same time, questions and criticisms have arisen about how this medicine is supplied and the level of support provided by the government and responsible institutions to patients.

Ayeh Deris, a member of the editorial team of Iran International, reports on the program “Peyvast.”